annual numbersI was glad to see burn rate was significantly lower than 2022.
Hopefully the $12M cash on hand can last a while. I'd expect them to raise money for Phase 2 after the mid-year data becomes available.
It's a slow go but this market cap is still miniscule relative to the market opportunity if the lab data translates into the clinic.
2024 will be an exciting year.